Recent randomized trials have shown that completion axillary lymph node dissection were also considered in the final pathologic assessment (FPA) (−) group that would not require a further axillary dissection, the revised NPV of INP and FPA were found to be 92.6% and 98.1%, respectively. The revised accuracy of INP also found to be increase to 86.9%. Our study, which is the only prospective one about palpation of dissected SLNs in the literature, suggests that INP can help to identify patients who do not need ALND, which encourages omitting IPA in cT1-2 N0 breast cancer.
Such complications would also significantly affect the patient's quality of life. With the inclusion of the SLNB concept, complication rates due to ALND were greatly reduced and similar survival rates have been achieved. 5, 6 Axillary nodal status has traditionally been the most important factor in staging breast cancer. 7 SLNB has being used in most centers for patients with clinically negative axilla and has gained acceptance as a predictor of axillary lymph node status with a reported accuracy of 95%-100%. 8, 9 If the sentinel lymph node (SLN) is positive and contains metastatic tumor cells, 13%-60% of patients will have positive non-sentinel axillary nodes. 8, 10, 11 The sensitivity and accuracy of intraoperative pathologic assessment (IPA) of SLNs have been reported to range from 36.0% to 93.3% and 83.2% to 96.0%, respectively. 8, 12, 13 With implementation of the American College of Surgeons Oncology Group (ACOSOG) Z0011 data, along with other randomized trials that showed completion ALND is not required in all patients with a positive SLN, routine IPA has recently become unnecessary in dedicated breast centers. [14] [15] [16] After Z0011, surgeons were less likely to perform intraoperative nodal assessment (26% vs 69%, P = 0.001), which resulted in decreased median operative times for patients who were SLN-negative at the MD Anderson Cancer Center. 17 This concept is accepted by many of the breast surgeons and unit in the United States and European countries. Although intraoperative assessment of sentinel lymph nodes has become less necessary in the post-Z11 era, surgeons continue to request IPA. Therefore, we sought to determine the accuracy of INP vs IPA. 
| Surgical and intraoperative palpation procedure
After induction of general anesthesia, isosulfan blue and/or radio-colloid was injected to the deep subareolar tissue. All dissected sentinel and non-SLNs were palpated by the primary surgeon and their predictions were recorded separately for all dissected nodes at that time. There were seven different breast-specific surgeons in cohort A and three in cohort B. Even though it is a subjective evaluation, Subsequent to SLNB, BCS or mastectomy was decided depending on patient and tumor characteristics.
| Intraoperative pathologic assessment of sentinel lymph nodes
Sentinel lymph nodes were sent to the pathology laboratory directly from the operating room during the operation. All sentinel lymph nodes were dissected and routinely examined with touch imprint cytology. The slides were stained with hematoxylin and eosin (H and E). If there were not enough cells on the slide, scrape cytology was performed. Frozen section was used occasionally when there was still a doubt of metastasis after scrape cytology.
| Final pathologic assessment
Tissues were fixed with 10% formalin for 24-48 hours at room temperature. Samples from the sentinel lymph nodes were placed in embedding cassettes. After standard tissue processing (nearly 10 hours) in a tissue processer, samples were embedded in paraffin and sectioned using a microtome. Five to ten 4-µm-thick serial sections were floated on the surface of a 37°C water bath with a brush and picked up on glass slides. Finally, the slides were placed in a 65°C oven for 20 minutes before undergoing the standard hematoxylin and eosin staining process. We routinely examine sentinel lymph nodes with serial sections. Four sections are prepared for each half of the sentinel lymph node. The third section is stained with pancytokeratin and the others are stained with H and E.
| Data collection and statistical analysis
In this prospective multicenter study, patients' data were collected on a specific study datasheet. All data including INP findings were collected prospectively and compared with the IPA and final pathologic assessment (FPA) results. Statistical analyses were performed using SPSS 17.0 for Windows software (SPSS Inc, Chicago, IL, USA).
Descriptive statistical methods (median, number, and percentage)
were used for analyzing the demographic data. INP and IPA data were compared with FPA findings, and χ 2 analyses were used to assess for differences. All P-values were two-sided, and P < 0.05 was considered to indicate statistical significance.
| RESULTS

Patient characteristics including demographic data and descriptive
analyses are shown in (57.1%) were also IPA negative. ALND was performed in 12 patients (32.4%), and none had three or more metastases; only one had extracapsular involvement with a diameter of 4 mm ( Table 3) . Three patients had micrometastasis in only one lymph node. To assess the results in an unbiased manner, these 12 patients were discussed in the multidisciplinary tumor board as they only had SLNB not ALND. were found as 72.7% and 92.6%, respectively. Thus, we can correctly predict almost 93% of the patients with negative axilla. The revised accuracy also found to increase up to 86.9% (Table 4) . 14 At a median follow-up of 6.3 years, there was no difference in locoregional recurrence, overall survival (OS), and disease-free survival (DFS) rates. In the IBCSG 23-01 trial, similarly, no significant difference was found in DFS, OS, and cumulative incidence rates between the no-ALND and ALND-group in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumor of maximum 5 cm in diameters at a median follow-up of 5 years. 15 Finally, in the recently published AMAROS trial, Rutgers et al concluded that ALND and axillary radiotherapy after a positive SLN provided excellent and comparable axillary control for patients with T1-2 primary breast cancer and no palpable lymphadenopathy after a median follow-up of 6.1 years. 16 In the 2014 American Society of Clinical
Oncology clinical practice guideline update, the concept of omitting ALND in a specific group of patients with low-risk axillary involvement was therefore described for patients treated with BCS, WBI, and adjuvant systemic treatment. Overall, the rate of recall for ALND was 11.6%, compared with 8.4%
in T2-patients. The median time for IPA of SLN was 30 minutes, which is comparable with the findings of our study as "31 minutes".
This approach has been more cost-effective because the institution decreased its operational times and realized a 9.6% cost saving, as compared with the standard procedure as expected.
The sensitivity and accuracy of IPA of the SLN have been reported to range from 36.0% to 93.3%, and 83.2% to 96.0%, respectively. 8, 12, 13 The accuracy of IPA in our series was 94.1%, which is similar to the published literature. 8, 12, 13 The revised accuracy of INP improved to 87% when micrometastasis was considered in the FPA negative group, which could be considered a clinically feasible rate.
IPA is less effective in the detection of micrometastasis. 25 The sensitivity ranges between 10% and 52%. [26] [27] [28] [29] Almost half of cases with micrometastasis were not detected with IPA in our study, similar to the published literature. 30 Further analyses considering micrometastasis in the FPA negative group also showed that we only would have an error margin of approximately 7% in INP (−) group due to our revised NPV as 93%. In the INP (+) group, however, the revised error margin was 27% due to the revised PPV as 73%. Besides, of the 217 patients with INP (−), completion ALND was decided only for one patient (0.5%), and this rate is very low when we compare with decision rates of completion ALND in the literature. 23 Therefore, it seems to be more appropriate to send SLNs to IPA in the INP (+) group.
Current concept in breast cancer treatment is systematic and locoregional treatment incorporated with biological tumor behavior.
BCS followed by WBI therapy effectively prevent axillary recurrence in clinically node negative breast cancer patients which may contain certain micrometastasis or low tumor burden macrometastasis. 14, 15 This concept mainly depending on dedicated imaging of the axilla, preoperatively axillary palpation which detect overt axillary metastasis and may be more importantly INP. ALND rarely advised in cases which adjuvant treatment (Radiation field, systemic treatment choices) decision will be affected.
To assess the reproducibility of our study, patients from 2 different cohorts were included into our study. Even though there might be some variations in experiences between surgeons in these 2 different breast clinics, the findings regarding NPV, PPV, and accuracies were almost comparable between the 2 cohorts. However, it should be kept in mind that almost all of the surgeons who participated in this study are dedicated breast surgeons. Therefore, it might be useful to investigate surgeons from general surgery clinics who are not dedicated breast surgeons to assess the feasibility and reproducibility of this study in future.
| CONCLUSION
Axillary lymph node dissection is still being used in many clinics around the world. At our institution, ALND was omitted in the majority of patients with micrometastatic disease before the results of the Z0011 trial were released. However, after the Z0011 trial, our indications to omit ALND have been widened even though we still send SLNs for IPA.
In this study, which is the only prospective study about palpation of dis- 
